Patents by Inventor Parvez Vora

Parvez Vora has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENETICALLY ENGINEERED CELLS HAVING ANTI-CD133 / ANTI-EGFR CHIMERIC ANTIGEN RECEPTORS, AND USES THEREOF
    Publication number: 20250090582
    Abstract: Provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof expressing mono- and/or bi-specific chimeric antigen receptors (CAR) with anti-CD133 and anti-EGFR antigen binding domains, and methods of using the same. Also provided are compositions, polypeptides, vectors, and methods of manufacturing.
    Type: Application
    Filed: June 8, 2023
    Publication date: March 20, 2025
    Applicant: Century Therapeutics, Inc.
    Inventors: Michael Francis NASO, Jill Marinari CARTON, Parvez VORA, Luis BORGES, Christopher DOWER, Daren BLOEMBERG
  • CD133-BINDING AGENTS AND USES THEREOF
    Publication number: 20220073640
    Abstract: This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.
    Type: Application
    Filed: October 26, 2021
    Publication date: March 10, 2022
    Inventors: Jason Moffat, Jarrett Adams, Guohua Pan, Sachdev Sidhu, Rashida Williams, Xiaoyu Zhang, Sheila K. Singh, Parvez Vora, Chitra Venugopal
  • CD133-binding agents and uses thereof
    Patent number: 11220551
    Abstract: This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: January 11, 2022
    Assignees: The Governing Council of the University of Toronto, McMaster University
    Inventors: Jason Moffat, Jarrett Adams, Guohua Pan, Sachdev Sidhu, Rashida Williams, Xiaoyu Zhang, Sheila K. Singh, Parvez Vora, Chitra Venugopal
  • CD133-BINDING AGENTS AND USES THEREOF
    Publication number: 20190330362
    Abstract: This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.
    Type: Application
    Filed: October 19, 2017
    Publication date: October 31, 2019
    Inventors: Jason Moffat, Jarrett Adams, Guohua Pan, Sachdev Sidhu, Rashida Williams, Xiaoyu Zhang, Sheila K. Singh, Parvez Vora, Chitra Venugopal